As a result of our exploratory programme aimed at elaborating
dually acting compounds towards the serotonin (5-HT) transporter
(SERT) and the 5-HT2C receptor a novel series of 3-amino-1-
phenylpropoxy substituted diphenylureas was identified. From
that collection two promising compounds (2 and 3) exhibiting
highest 5-HT2C receptor affinity strongly inhibited the 5-HT2C
receptor agonist 1-(3-chlorophenyl)piperazine (mCPP) induced
hypomotility in mice. In further pursuance of that objective (2-
aminoethyl)(benzyl)sulfamoyl diphenylureas and
diphenylpiperazines have also been elaborated. Herein we report
the synthesis of potent multiple-acting compounds from this new
class. However, when two optimized representatives (6 and 14)
possessing the desired in vitro profile were tested neither
reduced the motor activity of mCPP treated animals. Comparative
albeit limited in vitro structure-activity relationship (SAR)
analysis and detailed in vivo studies are discussed and
explanation for their intricate behaviour is proposed.